Clinical Trial

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, randomized Phase 2 trial to evaluate the efficacy of NALIRIFOX (Arm 1) vs mGAP (Arm 2) in previously untreated patients with locally advanced (unresectable) and metastatic pancreatic ductal adenocarcinoma (PDAC).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-14; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Recruiting 2025-11-10
Trial Details
NCT Number NCT07076212
Lead Sponsor Medical University of South Carolina
Conditions Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Enrollment 52 participants
Start Date 2026-04-02
Primary Completion 2028-05 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-06